Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.60 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598195 | 0.87 | IRAK4 (0.67) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598629 | 0.86 | IRAK4 (0.63) | IRAK4IRAK1NTRK1 | |
| SCHEMBL20598638 | 0.85 | IRAK4 (0.72) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598097 | 0.84 | IRAK4 (0.71) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598190 | 0.84 | IRAK4 (0.72) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL23896445 | 0.84 | IRAK4 (0.55) | IRAK4IRAK1MAPKAPK2NTRK1PIK3CD | |
| SCHEMBL20598160 | 0.82 | IRAK4 (0.61) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598069 | 0.82 | IRAK4 (0.61) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598580 | 0.82 | IRAK4 (0.61) | IRAK4IRAK1NTRK1NTRK2 | |
| SCHEMBL20598338 | 0.80 | IRAK4 (0.59) | IRAK4IRAK1NTRK1NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885IRAK1 1/4885MAPKAPK2 62/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885IRAK1 1/4885MAPKAPK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.